Compare PGEN & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | OPRA |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | Norway |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2013 | 2018 |
| Metric | PGEN | OPRA |
|---|---|---|
| Price | $3.81 | $18.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $8.33 | ★ $21.50 |
| AVG Volume (30 Days) | ★ 4.0M | 340.3K |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.61% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $1,115.92 | $21.29 |
| Revenue Next Year | $81.04 | $15.34 |
| P/E Ratio | ★ N/A | $13.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $11.71 |
| 52 Week High | $5.47 | $21.06 |
| Indicator | PGEN | OPRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.10 | 54.05 |
| Support Level | $3.49 | $13.08 |
| Resistance Level | $4.40 | $19.24 |
| Average True Range (ATR) | 0.29 | 0.60 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 2.97 | 56.98 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.